These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 18481066)
1. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera. Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066 [TBL] [Abstract][Full Text] [Related]
2. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis]. Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505 [TBL] [Abstract][Full Text] [Related]
3. Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Kuriakose E; Vandris K; Wang YL; Chow W; Jones AV; Christos P; Cross NC; Silver RT Haematologica; 2012 Apr; 97(4):538-42. PubMed ID: 22102708 [TBL] [Abstract][Full Text] [Related]
4. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351 [TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission. Larsen TS; Møller MB; de Stricker K; Nørgaard P; Samuelsson J; Marcher C; Andersen MT; Bjerrum OW; Hasselbalch HC Hematology; 2009 Dec; 14(6):331-4. PubMed ID: 19941739 [TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111 [TBL] [Abstract][Full Text] [Related]
7. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836 [TBL] [Abstract][Full Text] [Related]
8. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759 [TBL] [Abstract][Full Text] [Related]
9. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929 [TBL] [Abstract][Full Text] [Related]
10. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea. Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451 [TBL] [Abstract][Full Text] [Related]
11. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851 [TBL] [Abstract][Full Text] [Related]
13. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244 [TBL] [Abstract][Full Text] [Related]
14. Presence of the JAK2 V617F mutation in a patient with chronic neutrophilic leukemia and effective response to interferon α-2b. Zhang X; Pan J; Guo J Acta Haematol; 2013; 130(1):44-6. PubMed ID: 23391844 [TBL] [Abstract][Full Text] [Related]
15. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]. Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211 [TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera. Illés Á; Pinczés LI; Egyed M Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451 [TBL] [Abstract][Full Text] [Related]
19. Can pegylated interferon improve the outcome of polycythemia vera patients? Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927 [TBL] [Abstract][Full Text] [Related]